Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
[PDF][PDF] Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
M Tuccori, S Ferraro, I Convertino, E Cappello… - 2020 - scienceopen.com
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
[HTML][HTML] Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
M Tuccori, S Ferraro, I Convertino, E Cappello… - mAbs, 2020 - ncbi.nlm.nih.gov
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
M Tuccori, S Ferraro, I Convertino, E Cappello… - …, 2020 - pubmed.ncbi.nlm.nih.gov
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.
M Tuccori, S Ferraro, I Convertino, E Cappello… - Mabs, 2020 - europepmc.org
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
[引用][C] Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
M Tuccori, S Ferraro, I Convertino, E Cappello… - mAbs, 2020 - cir.nii.ac.jp
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
M Tuccori, S Ferraro, I Convertino, E Cappello… - MABS, 2020 - irinsubria.uninsubria.it
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
M Tuccori, S Ferraro, I Convertino, E Cappello… - MABS, 2020 - arpi.unipi.it
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline.
M Tuccori, S Ferraro, I Convertino, E Cappello… - Mabs, 2020 - europepmc.org
Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …
as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 …